FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564746987> ?p ?o ?g. }

• W2564746987 abstract "Introduction: The purpose of this research was to investigate the anti-tumor effect of BPI-2009H and BPI-403B, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in the human pancreatic cancer cell lines BxPC-3 and Panc-1, in vitro and in vivo and determine the maximum tolerated dose (MTD) of the compound in mouse. Experimental Design: In vitro, human pancreatic cancer cell lines, BxPC-3 and Panc-1 were exposed to varying concentrations of BPI-2009H and BPI-403B, the concentration of compound required to inhibit growth by fifty percent (IC50) was estimated. In vivo, tumor growth inhibition of low dose BPI-2009H was tested in xenografted nude mice with BxPC-3 pancreatic cancer tumors. The maximum tolerated dose (MTD) was established via oral administration of low, mid and high doses to Harlan mice of both BPI-2009H and BPI-403B. Upon determination of the MTD, the in vivo efficacy of high dose BPI-2009H was evaluated via tumor growth inhibition study on xenografted nude mice with BxPC-3 pancreatic cancer tumors. Results: BPI-2009H, as a single agent, inhibited the growth of BxPC-3 cells in a dose dependent manner, with a relative IC50 value of 25.8 μM. BPI-403B, as a single agent, inhibited growth of BxPC-3 cells in a dose dependent manner as well, with a relative IC50 value of 2.7 μM. BPI-2009H and BPI-403B were tested up to 50μM in Panc-1 cells with no apparent effect at the upper limit of the study for either of the compounds. In vivo, the mice treated with BPI-403B demonstrated a statistically significant tumor growth delay, 14.3 days. 20% of the mice experienced tumor regression. The compound was well tolerated with minimal body weight loss. At low doses, BPI-2009H did not show any statistically significant tumor growth delay, but upon increasing the dose to the MTD, significant signs of anticancer activity was demonstrated, with an increase in tumor growth delay. Conclusions: The in vitro and in vivo findings show that both BPI-2009H and BPI-403B have antiproliferative effects against BxPC-3 pancreatic cancer cells. These compounds are both well tolerated and may prove to be an alternative option of EGFR-TKI to erlotinib treatment in pancreatic cancer cases. Citation Format: Victoria Lynn Wilde, Don Zhang, Jirong Peng, Michael A. Green, Michael N. Greco, Michael Costanzo. Anti-tumor activity of icotinib (BPI-2009H) and BPI-403B in the BxPC-3 pancreatic cancer cell line. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2592. doi:10.1158/1538-7445.AM2015-2592" @default.
• W2564746987 created "2017-01-06" @default.
• W2564746987 creator A5011100896 @default.
• W2564746987 creator A5011600721 @default.
• W2564746987 creator A5013547298 @default.
• W2564746987 creator A5042944827 @default.
• W2564746987 creator A5052516607 @default.
• W2564746987 creator A5082309912 @default.
• W2564746987 date "2015-08-01" @default.
• W2564746987 modified "2023-09-27" @default.
• W2564746987 title "Abstract 2592: Anti-tumor activity of icotinib (BPI-2009H) and BPI-403B in the BxPC-3 pancreatic cancer cell line" @default.
• W2564746987 doi "https://doi.org/10.1158/1538-7445.am2015-2592" @default.
• W2564746987 hasPublicationYear "2015" @default.
• W2564746987 type Work @default.
• W2564746987 sameAs 2564746987 @default.
• W2564746987 citedByCount "0" @default.
• W2564746987 crossrefType "proceedings-article" @default.
• W2564746987 hasAuthorship W2564746987A5011100896 @default.
• W2564746987 hasAuthorship W2564746987A5011600721 @default.
• W2564746987 hasAuthorship W2564746987A5013547298 @default.
• W2564746987 hasAuthorship W2564746987A5042944827 @default.
• W2564746987 hasAuthorship W2564746987A5052516607 @default.
• W2564746987 hasAuthorship W2564746987A5082309912 @default.
• W2564746987 hasConcept C121608353 @default.
• W2564746987 hasConcept C126322002 @default.
• W2564746987 hasConcept C150903083 @default.
• W2564746987 hasConcept C185592680 @default.
• W2564746987 hasConcept C202751555 @default.
• W2564746987 hasConcept C207001950 @default.
• W2564746987 hasConcept C2777752497 @default.
• W2564746987 hasConcept C2778764654 @default.
• W2564746987 hasConcept C2778820342 @default.
• W2564746987 hasConcept C2779707156 @default.
• W2564746987 hasConcept C2780210213 @default.
• W2564746987 hasConcept C2780278673 @default.
• W2564746987 hasConcept C502942594 @default.
• W2564746987 hasConcept C55493867 @default.
• W2564746987 hasConcept C71924100 @default.
• W2564746987 hasConcept C86803240 @default.
• W2564746987 hasConcept C98274493 @default.
• W2564746987 hasConceptScore W2564746987C121608353 @default.
• W2564746987 hasConceptScore W2564746987C126322002 @default.
• W2564746987 hasConceptScore W2564746987C150903083 @default.
• W2564746987 hasConceptScore W2564746987C185592680 @default.
• W2564746987 hasConceptScore W2564746987C202751555 @default.
• W2564746987 hasConceptScore W2564746987C207001950 @default.
• W2564746987 hasConceptScore W2564746987C2777752497 @default.
• W2564746987 hasConceptScore W2564746987C2778764654 @default.
• W2564746987 hasConceptScore W2564746987C2778820342 @default.
• W2564746987 hasConceptScore W2564746987C2779707156 @default.
• W2564746987 hasConceptScore W2564746987C2780210213 @default.
• W2564746987 hasConceptScore W2564746987C2780278673 @default.
• W2564746987 hasConceptScore W2564746987C502942594 @default.
• W2564746987 hasConceptScore W2564746987C55493867 @default.
• W2564746987 hasConceptScore W2564746987C71924100 @default.
• W2564746987 hasConceptScore W2564746987C86803240 @default.
• W2564746987 hasConceptScore W2564746987C98274493 @default.
• W2564746987 hasLocation W25647469871 @default.
• W2564746987 hasOpenAccess W2564746987 @default.
• W2564746987 hasPrimaryLocation W25647469871 @default.
• W2564746987 hasRelatedWork W1543550567 @default.
• W2564746987 hasRelatedWork W1772075522 @default.
• W2564746987 hasRelatedWork W1964562035 @default.
• W2564746987 hasRelatedWork W1966065696 @default.
• W2564746987 hasRelatedWork W1967647337 @default.
• W2564746987 hasRelatedWork W1968591284 @default.
• W2564746987 hasRelatedWork W2025313715 @default.
• W2564746987 hasRelatedWork W2034557574 @default.
• W2564746987 hasRelatedWork W2035948588 @default.
• W2564746987 hasRelatedWork W2051833042 @default.
• W2564746987 hasRelatedWork W2088029388 @default.
• W2564746987 hasRelatedWork W2173607716 @default.
• W2564746987 hasRelatedWork W2499644901 @default.
• W2564746987 hasRelatedWork W2556211322 @default.
• W2564746987 hasRelatedWork W2562145343 @default.
• W2564746987 hasRelatedWork W2566462879 @default.
• W2564746987 hasRelatedWork W2607719451 @default.
• W2564746987 hasRelatedWork W2740784890 @default.
• W2564746987 hasRelatedWork W2956085470 @default.
• W2564746987 hasRelatedWork W2981504976 @default.
• W2564746987 isParatext "false" @default.
• W2564746987 isRetracted "false" @default.
• W2564746987 magId "2564746987" @default.
• W2564746987 workType "article" @default.